Samsung Biologics CDO Services Brochure

Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. 

Your Trusted CDMO Partner, Samsung Biologics

Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. 

In this written panel discussion experts in manufacturing in the pharmaceutical supply chain comment on the manufacturing landscape, how sustainable practices are being incorporated more readily, the challenges associated with this and the overall advantages. 

A company’s strategy is crucial for determining future success, and therefore, it needs to constantly change in line with market dynamics. Although building in-house offer the advantage of direct control, the time, labor, and spend required to implement this often makes it the inefficient choice. From this whitepaper, you will learn about the parameters to consider when selecting a CDMO.

Samsung Biologics, the leading end-to-end CDMO, is set to start building a new plant based in North Korea, to expand its biomanufacturing capabilties. 

Manufacture The Future 

Imagine a future

Where ideas become cures

A future 
where innovation and technology 
help pioneer endless possibilities 
to make a lasting impact 

A future
Where efficiency meets expertise
Collaboration enables customizationDedication empowers breakthroughs

This is a place where we help your ingenuity 
to build a better future

A future we all want to live in.

Samsung Biologics

Samsung Biologics has been awarded The Terra Carta Seal from the sustainable markets initiative.

In recent years, the standardization of biologics manufacturing processes has given product developers multiple viable options for producing biologics. These options include building an in-house production system or partnering with a contract biologics manufacturer. Although building in-house does offer the advantage of direct control; the time, labor, and spend required to implement this often makes it the inefficient choice. On the other hand, working with an experienced contract manufacturer can help you save time and costs by leveraging a deep pool of industry experience. However, the process of selecting the right CDMO partner needs to be performed after careful analysis of many factors: any of which, if overlooked, can create risk of delay or cost overrun. In this session, we will discuss the key parameters that you can easily assess when choosing the right innovative CDMO partner that will keep you competitive in a rapidly evolving market.

In this interview with Jimin Han, Director of Climate Change in Business Strategy Team at Samsung Biologics (Incheon, South Korea), we discuss trends in the global biologics market, the biggest opportunities and challenges for this sector, and the growing consciousness surrounding sustainable practices for biologics developers and manufacturers.

Today, leading companies are not only centered on creating values, but they also focus on developing strategies to foster a company's longevity. Therefore, many companies have become more engaged in sustainable activities to make progress and are now joining the race. Acknowledging the importance of sustainable development, Biopharma CDMO companies are also finding ways to show their best performances in sustainability.
In this session, we will discuss the importance of why pharmaceutical CDMO companies should make their transition with long-term sustainability in mind. Explaining how the pharmaceutical industry (and innovative initiatives) should put effort into improving outcomes for patients, employees, the environment, and the wider community. Learn how Samsung Biologics, as one of the leading CDMO companies, is committed to making a sustainable future by creating ESG values through climate change responses, entry into the carbon neutral society, and transparency in the governance structure.

With new drug approvals hitting a record high in 2021 and unprecedented number of out-licensing deals closed in 2020, Korean pharmaceutical companies and CDMO’s are poised for significant market growth [i].

CDMO currently manufacturing LAAB combination treatment  and will start on cancer immunotherapy product from next year

Samsung to provide end-to-end CDMO services to advance Kineta's novel anti-VISTA antibody for the treatment of solid tumours

Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told